RESEARCH
Nova Neurology collaborates with the QEII Health Sciences Center and Centricity Research (located in the same building but independent) to engage in cutting edge research in area of Movement Disorders. Please contact our research coordinator for further information.
CURRENT RESEARCH STUDIES
Please scroll to the bottom for our most recent studies
ENROLL-HD (RECRUITING)
Enroll-HD is a worldwide observational study for Huntington’s disease families. It will monitor how the disease appears and changes over time in different people, and is open to people who either have HD or are at-risk. Further information can be found at https://www.enroll-hd.org/
GENERATION-HD (ONGOING, RECRUITMENT CLOSED)
The GENERATION HD1 study will evaluate the efficacy and safety of RG6042 treatment given once every two months (bi-monthly) or once every four months (16-weeks) over a period of 25 months (approx. two years). Participants will be randomized to one of three treatment study arms: bi-monthly, every four months or placebo bi-monthly. This means for every two participants randomized to RG6042, one will receive placebo. The study is designed to test the potential effects of RG6042 compared to placebo. The study is “double-blind” meaning neither the participant nor his/her investigator or site staff will know which study arm the participant is assigned. Further information can be found at https://www.huntingtonsociety.ca/generation-hd1/
24-HOUR DAILY EXPOSURE OF CONTINUOUS SUBCUTANEOUS INFUSION OF ABBV-951 (RECRUITMENT CLOSED)
The purpose of this study is to assess the safety and tolerability of ABBV-951 in subjects with Parkinson's disease (PD).
PRIDOPIDINE OUTCOME ON FUNCTION IN HUNTINGTON DISEASE PATIENTS (PROOF-HD) (RECRUITMENT CLOSED)
Further information on this study will be posted when available.
Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults (RECRUITING)
This Phase 2 trial will evaluate the efficacy and safety of ABP-450 for migraine prevention in adults who suffer from six or more migraine days per month. The study will enroll 690 patients across approximately 60 sites in the United States, Canada and Australia. Study subjects will be divided evenly across a low dose group, a high dose group and a placebo group.
A Clinical Trial of PRAX-944 in Participants With Essential Tremor (RECRUITING)
This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor. Part A is designed to study the dose titration from 20 to 40 mg every morning (QAM) (ie, 2 weeks with 7 days at each dose level). Part B is designed to study the dose titration from 20 to up to 120 mg QAM with at least 14 days of dosing at the highest tolerated dose for each participant. Blood levels of PRAX-944 will also be measured throughout the trial and pharmacokinetics will be evaluated.
ES Therapeutics Essential Tremor Study (NOT YET RECRUITING)
Details pending